Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Ephrin Receptor
    (2)
  • BTK
    (1)
  • Bcr-Abl
    (1)
  • EGFR
    (1)
  • ERK
    (1)
  • PPAR
    (1)
  • Prostaglandin Receptor
    (1)
  • ROCK
    (1)
  • Rho
    (1)
  • Others
    (1)
Filter
Search Result
Results for "

tyrosine kinase-in-8

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    7
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    2
    TargetMol | Peptide_Products
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
Tyrosine kinase-IN-8
T209700
Tyrosine kinase-IN-8 (compound 4e) is a BCR‐ABL1 tyrosine kinase inhibitor (TKI) exhibiting antiproliferative activity against the chronic myeloid leukemia (CML) cell line K562, with a CC50 of 0.8 µM. Tyrosine kinase-IN-8 is applicable for research in chronic leukemia.
  • Inquiry Price
Inquiry
Size
QTY
BMX-IN-1
BMX kinase inhibitor
T146921431525-23-3
BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton's tyrosine kinase (BTK, IC50 = 10.4 nM), but BMX-IN-1 is more than 47-656 fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.
  • $30
In Stock
Size
QTY
8-iso Prostaglandin F1β
T3616326771-95-9
8-iso Prostaglandin F1β, an isoprostane produced from arachidonic acid, induces concentration-dependent vasoconstrictor effects in pulmonary arteries (PA), pulmonary veins (PV) and mesenteric arteries (MA) through the activation ofTXA2R, tyrosine kinase and Rho kinase.
  • $316
35 days
Size
QTY
EGFR-IN-23
T731042747133-37-3
EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.05 nM against the BaF3/EGFR-DEL19/T790M/C797S cell line.
  • $2,270
10-14 weeks
Size
QTY
Anticancer agent 231
T88660128519-30-2
Anticanceragent 231 (compound P5) is a tyrosine kinase inhibitor with an IC50 value of 3.95 μM. It targets the EGFR-ERK1/2 signaling pathway, reducing cell viability, proliferation, migration, and cancer stemness in triple-negative breast cancer (TNBC) cells, potentially playing a significant role in the treatment of TNBC.
  • $1,520
4-6 weeks
Size
QTY
KYL peptide
KYL
TP1895676657-00-4
KYL peptide is an EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM); inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM). Prevents AβO induced synaptic damage, dendritic spine loss and prevents the blocking of LTP in hippocampal CA3-CA1 transmissions. Exhibits a long half life in cell culture media (8 and 12 hours in PC3 and C2C12 media respectively). Neuroprotective.
  • $816
35 days
Size
QTY
KYL acetate(676657-00-4 free base)
TP1895L1
KYL acetate is an EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM); inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM). Prevents AβO induced synaptic damage, dendritic spine loss and prevents the blocking of LTP in hippocampal CA3-CA1 transmissions. Exhibits a long half life in cell culture media (8 and 12 hours in PC3 and C2C12 media respectively). Neuroprotective.
  • $133
In Stock
Size
QTY